LexisNexis® Legal Newsroom
CompPharma Publishes Terms and Definitions for Workers' Compensation Pharmacy Industry

MADISON , CT – CompPharma ( www.comppharma.com ), a consortium of workers' compensation pharmacy benefit managers (PBMs), has compiled a directory of terms and definitions describing various aspects of the workers' compensation pharmacy industry. "CompPharmaPedia," is available...

CA: WCAB Provides Guidance on Reimbursement of Lien for Repackaged Pharmaceuticals

Ramon Mendoza v. J. Buckbinder Industry, Inc., Insurance Company of the West Liens--Repackaged Pharmaceuticals--WCAB rescinded WCJ's finding that lien claimant California Pharmacy Management was entitled to partial reimbursement of its lien for repackaged drugs dispensed by treating physician...

PMSI Releases 2010 Annual Drug Trends Report

Tampa, FL (CompNewsNetwork) - PMSI, one of the nation’s largest providers of specialty products and services for the workers’ compensation market, today announced the release of its 2010 Annual Drug Trends Report. The report represents one of the most extensive analyses of workers’...

CWCI Research Tracks the Continued Growth of California Workers’ Comp Medical Expenses

California workers’ compensation medical expenditures fell sharply immediately after the enactment of the 2002-2004 reforms, but that decline was short-lived, and after rising steadily since 2005, average payments for treatment, pharmaceuticals and durable medical equipment (DME), medical management...

Pharmaceuticals, Drinking Water, and Liability

By Dianne Saxe, Ontario Environmental Lawyer The better our detection ability becomes, the more things we find in the water. One important group of those things is pharmaceuticals and their metabolites. Pharmaceuticals are specifically designed to affect the bodies, brains and behaviour of humans...

Are Municipalities Liable For Pharmaceuticals In Drinking Water?

By Dianne Saxe, Ontario Environmental Lawyer The better our detection ability becomes, the more things we find in the water. One important group of those things is pharmaceuticals and their metabolites. Pharmaceuticals are specifically designed to affect the bodies, brains and behaviour of humans...

NCCI Addresses Workers’ Compensation Prescription Drugs Costs

Increased Utilization of Predominantly Expensive Drugs Fuel Cost Rise An August 2011 research brief by the National Council on Compensation Insurance, Inc. (NCCI) analyzed the trend of prescription drugs constituting a disproportionately high percentage of workers' compensation expenses. The...

Brinks Hofer Gilson & Lione: Supreme Court Issues Key Ruling Regarding Pharmaceutical Litigation

On April 17, 2012, the Supreme Court issued a unanimous decision favorable to generic pharmaceutical companies in Caraco Pharmaceuticals, Ltd. v. Novo Nordisk , No. 10-844 [ enhanced version available to lexis.com subscribers ]. The Court held that a generic pharmaceutical company may pursue a counterclaim...

Duane Morris LLP: U.S. Supreme Court Restores Generic Pharma's Ability to Challenge Orange Book Use Code Information

The U.S. Supreme Court's unanimous ruling on April 17, 2012, in Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S was a resounding win for both Caraco and the generic pharmaceutical industry as a whole. Specifically, the Court held that a generic manufacturer may employ the counterclaim...

Sunstein Kann Murphy & Timbers LLP: Pharmaceutical Companies Take Heed — Compulsory Patent License Is Awarded in India

By Thomas Carey and Nancy C. Wilker, Ph.D. As part of the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS), a signatory country can allow someone to produce a patented product or process without the patent owner's consent. The grounds for justifying a grant of a compulsory...

Sheppard Mullin Richter & Hampton LLP: Section viii Statements -- Still A Viable Route to Generic Approval Where the Application Is Not Claimed in an Orange Book Patent

By Nagendra Setty and Mark E. McGrath In its recent decision in AstraZeneca Pharmaceuticals LP v. Apotex Corp ., Nos. 2011-1182 - 2011-1190 (Fed. Cir. Feb. 9, 2012) (hereinafter the " AstraZeneca Decision") (Rader*, Bryson & Linn), the Federal Circuit affirmed a District of Delaware...

CWCI Study Tracks Growth of California Workers’ Comp Medical Payments

A new CWCI study on changes in California workers’ compensation medical payments finds that since accident year (AY) 2005 – the first year after the last round of workers’ compensation reforms – the average amounts insurers pay for medical services on work injury claims have jumped...

Reverse Payments by Drug Companies: The Supreme Court Declines to Adopt a Bright-Line Test

by Thomas Carey and Nancy Chiu Wilker Ph.D. Excerpt: The Federal Trade Commission has long opposed "reverse payments," the practice by which a pioneer drug company selling a brand-name drug pays a generic drug company to not enter the market. These payments arise in connection with the...

Pharmacists bottles

U.S. House Introduces Bill on Federal Oversight of Compounding Pharmacies

On September 12, 2013, U.S. Representative Morgan Griffith (R-Va.) introduced H.R. 3089 ("the House Bill") [ enhanced version available to lexis.com subscribers ], which proposes a structure for federal oversight of compounding pharmacies. The House Bill is the latest federal proposal for regulating...

Physician's Failure To Read Trumps Drug Company's Failure To Warn

When the prescribing physician in a pharmaceutical product liability case admits that at her deposition that she never reviewed the manufacturer’s label before treating her patient and that the label played no role in her decision to prescribe the drug, plaintiff’s claim that the label should...

FDA Releases Draft Guidance on Section 503B Fees for Drug Compounding Outsourcing Facilities; Details Process for Paying and Calculating Fees

On April 1, 2014, the U.S. Food and Drug Administration (FDA) published notice of its Draft Guidance for Industry on Fees for Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and Cosmetic Act ("Draft Guidance"), which sets forth FDA's current thinking on the annual...

FDA Releases Guidance for Industry on ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers

The U.S. Food and Drug Administration (FDA) recently published a new Guidance for Industry, titled ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers , which provides answers to questions from public comments received on the draft Guidance for Industry on ANDAs: Stability...

CWCI Study Monitors California Workers’ Comp Medical and Indemnity Trends

Payments for pharmaceuticals and durable medical equipment (DME) in California workers’ compensation continue to increase sharply, adding pressure against the recent reforms to the system according to a new CWCI study that examines medical and indemnity payment trends from accident years (AY) 2002...

Purchase of Accounts Receivable Not a Trade Secret: Cal. Comp. Cases December Advanced Postings (11/25/2014)

Here’s the second batch of advanced postings for December 2014 issue of Cal. Comp. Cases. Lexis.com and Lexis Advance subscribers can link to the case to read the complete headnotes and summaries. © Copyright 2014 LexisNexis. All rights reserved. Landmark Medical Management, Petitioner...

DEA Releases Final Rule on Disposal of Controlled Substances

The U.S. Drug Enforcement Administration (DEA) has released notice of a final rule governing the disposal of controlled substances (the "Final Rule"). The Final Rule implements the Secure and Responsible Drug Disposal Act of 2010 (the "Disposal Act"), and according to the DEA, "generally...

Price Controls on Specialty Pharmaceuticals: Global Perspectives on the Free Market Debate

Karen C. Yotis, Esq., a Feature Resident Columnist for the LexisNexis Workers’ Compensation eNewsletter , provides insights into workplace issues and the nuts and bolts of the workers’ comp world. We love our pharmaceuticals here in the U S of A and we pay through the nose for them too...